



For immediate release

### **Aciont® To Present at ARVO 2009 Annual Meeting**

Salt Lake City, UT – May 1, 2009 – Aciont Inc. will present two of its Visulex® passive diffusion based topical application technologies at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting at the Greater Fort Lauderdale Convention Center. Both posters can be viewed on Thursday, May 7, 2009 from 10:15 AM—1:00 PM in Hall B/C at two separate poster sessions. Aciont personnel will be in attendance at the ARVO meeting to respond to questions regarding Aciont's work. The posters are entitled:

- "A Sustained Release System of Dexamethasone Sodium Phosphate with Calcium Ion Delivered from a Visulex® Passive Lens Device." Poster# A619.
- "Transscleral Passive Delivery of Dexamethasone Sodium Phosphate Plus Oxymetazoline: A Noninvasive Single Dose Treatment of EIU in Rabbit." Poster# D703.

"These two presentations demonstrate that the Visulex topical application, passive diffusion based system potentially can deliver a therapeutically relevant dose of steroid therapy to the back of the eye," said John Higuchi, Aciont's CEO. "The presentations also illustrate the potential advantage of incorporating a sustained release depot formulation in order to treat effectively a severe uveitis condition," Higuchi added.

"We are excited to present our Visulex technologies at ARVO," said Dr. Kongnara Papangkorn, Aciont's Senior Scientist presenting at the poster sessions. "The results are encouraging because they show that a simple noninvasive device with a right formulation can be as effective as injections and yet easy to use," Papangkorn added. The novel sustained release topical formulations performed better in the endotoxin induced uveitis model in rabbit (EIU) over conventional treatments including injections of the same steroid without the sustained released agents. The Visulex treatment was effective against the EIU using wear times of its scleral lens shaped applicator design as short as five minutes.

---

Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont's goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont® is located in Salt Lake City, Utah. For more information, visit the company's website at [www.aciont.com](http://www.aciont.com).

Source: Aciont Inc.

#### Contact

John Higuchi  
President/CEO  
Aciont® Inc.  
(801) 359-3461